Wedbush reiterated their buy rating on shares of Obseva (NASDAQ:OBSV) in a research report released on Monday, The Fly reports. They currently have a $34.00 price target on the stock, down from their previous price target of $40.00.
Several other equities research analysts have also recently commented on OBSV. Zacks Investment Research cut Obseva from a hold rating to a sell rating in a research note on Thursday, February 6th. Royal Bank of Canada upped their price target on Obseva from $18.00 to $19.00 and gave the stock an outperform rating in a research note on Tuesday, December 10th. Finally, HC Wainwright cut their price target on Obseva from $40.00 to $36.00 and set a buy rating for the company in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $23.25.
Shares of NASDAQ OBSV opened at $2.39 on Monday. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.54. Obseva has a twelve month low of $1.63 and a twelve month high of $14.50. The stock has a 50 day moving average of $2.98 and a two-hundred day moving average of $4.86. The stock has a market cap of $110.74 million, a P/E ratio of -0.95 and a beta of 0.66.
Obseva (NASDAQ:OBSV) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.10. As a group, research analysts predict that Obseva will post -2.02 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in OBSV. Wedbush Securities Inc. raised its stake in shares of Obseva by 242.4% during the fourth quarter. Wedbush Securities Inc. now owns 137,346 shares of the company’s stock worth $525,000 after purchasing an additional 97,238 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Obseva by 96.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,923 shares of the company’s stock worth $366,000 after purchasing an additional 47,012 shares during the last quarter. Ikarian Capital LLC purchased a new stake in shares of Obseva during the fourth quarter worth approximately $315,000. Acadian Asset Management LLC purchased a new stake in shares of Obseva during the fourth quarter worth approximately $60,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Obseva by 1,838.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,611 shares of the company’s stock worth $25,000 after purchasing an additional 6,270 shares during the last quarter. Institutional investors and hedge funds own 50.14% of the company’s stock.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Article: What is a stock portfolio tracker?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.